Cargando…
The optimal use of PEG-Asparaginase in relapsed ALL—lessons from the ALLR3 Clinical Trial
Autores principales: | Masurekar, A, Fong, C, Hussein, A, Revesz, T, Hoogerbrugge, P M, Love, S, Ciria, C, Parker, C, Krishnan, S, Saha, V |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4003420/ https://www.ncbi.nlm.nih.gov/pubmed/24769644 http://dx.doi.org/10.1038/bcj.2014.26 |
Ejemplares similares
-
Outcome of Central Nervous System Relapses In Childhood Acute Lymphoblastic Leukaemia – Prospective Open Cohort Analyses of the ALLR3 Trial
por: Masurekar, Ashish Narayan, et al.
Publicado: (2014) -
Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label randomised trial
por: Parker, Catriona, et al.
Publicado: (2019) -
Affordable and Safe Health Care for All Children: Lessons Learned from the Use of Peg-asparaginase in a Developing Country
por: Jayaraman, Dhaarani, et al.
Publicado: (2017) -
Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial
por: Parker, Catriona, et al.
Publicado: (2010) -
Diabetic ketoacidosis following PEG-asparaginase therapy
por: Ahmad, Miriam Hinaa, et al.
Publicado: (2018)